Journal
BIOORGANIC & MEDICINAL CHEMISTRY
Volume 21, Issue 22, Pages 7146-7154Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2013.09.003
Keywords
Choline kinase; Inhibitors; 3-Aminophenol; Docking studies
Funding
- Consejeria de Innovacion, Ciencia y Empresa, Junta de Andalucia [P07-CTS-03210]
- Ministerio de Ciencia e Innovacion [SAF2009-11955]
- Ministerio de Educacion
Ask authors/readers for more resources
Identification of novel and selective anticancer agents remains an important and challenging goal in pharmacological research. Choline kinase (ChoK) is the first enzyme in the CDP-choline pathway that synthesizes phosphatidylcholine (PC), the major phospholipid in eukaryotic cell membranes. In the present paper, a new family of non-symmetrical monocationic compounds is developed including a 3-aminophenol moiety, bound to 4-(dimethylamino)- or 4-(pyrrolidin-1-yl)pyridinium cationic heads through several linkers. The most promising compounds in these series as ChoK inhibitors are 3f and 4f, while compounds 3c, 3d and 4c are the better antiproliferative agents. The analysis of the biological data observed in the described series of compounds mays represents a platform for the design of more active molecules. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available